[go: up one dir, main page]

DK3810201T3 - GIP/GLP1-agonist-sammensætninger - Google Patents

GIP/GLP1-agonist-sammensætninger Download PDF

Info

Publication number
DK3810201T3
DK3810201T3 DK19739766.4T DK19739766T DK3810201T3 DK 3810201 T3 DK3810201 T3 DK 3810201T3 DK 19739766 T DK19739766 T DK 19739766T DK 3810201 T3 DK3810201 T3 DK 3810201T3
Authority
DK
Denmark
Prior art keywords
gip
agonist compositions
glp1 agonist
glp1
compositions
Prior art date
Application number
DK19739766.4T
Other languages
English (en)
Other versions
DK3810201T5 (da
Inventor
Vincent John Corvari
Christopher Sears Minie
Dinesh Shyandeo Mishra
Ken Kangyi Qian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67263049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3810201(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3810201T3 publication Critical patent/DK3810201T3/da
Publication of DK3810201T5 publication Critical patent/DK3810201T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19739766.4T 2018-06-22 2019-06-14 GIP/GLP1-agonist-sammensætninger DK3810201T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862688632P 2018-06-22 2018-06-22
PCT/US2019/037146 WO2019245893A2 (en) 2018-06-22 2019-06-14 Gip/glp1 agonist compositions

Publications (2)

Publication Number Publication Date
DK3810201T3 true DK3810201T3 (da) 2023-06-26
DK3810201T5 DK3810201T5 (da) 2023-08-21

Family

ID=67263049

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19739766.4T DK3810201T5 (da) 2018-06-22 2019-06-14 GIP/GLP1-agonist-sammensætninger

Country Status (34)

Country Link
US (5) US11357820B2 (da)
EP (2) EP3810201B9 (da)
JP (4) JP6896945B2 (da)
KR (4) KR102523489B1 (da)
CN (3) CN119424615A (da)
AR (1) AR115542A1 (da)
AU (3) AU2019289110B2 (da)
BR (1) BR112020023452A2 (da)
CA (1) CA3103469C (da)
CL (1) CL2020003359A1 (da)
CR (1) CR20200634A (da)
DK (1) DK3810201T5 (da)
EA (1) EA202092713A1 (da)
EC (1) ECSP20082717A (da)
ES (1) ES2953740T3 (da)
FI (1) FI3810201T3 (da)
HR (1) HRP20230748T1 (da)
HU (1) HUE063059T2 (da)
IL (2) IL279504B (da)
JO (1) JOP20200335A1 (da)
LT (1) LT3810201T (da)
MA (1) MA52965B1 (da)
MD (1) MD3810201T2 (da)
MX (2) MX2020013727A (da)
PE (2) PE20210049A1 (da)
PH (1) PH12020552215A1 (da)
PL (1) PL3810201T3 (da)
PT (1) PT3810201T (da)
RS (1) RS64288B9 (da)
SG (1) SG11202012744UA (da)
SI (1) SI3810201T1 (da)
TW (1) TWI705820B (da)
WO (1) WO2019245893A2 (da)
ZA (1) ZA202007162B (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
CA3107344A1 (en) * 2018-07-23 2020-01-30 Eli Lilly And Company Methods of using a gip/glp1 co-agonist for therapy
ES2993282T3 (en) 2018-07-23 2024-12-26 Lilly Co Eli Method of using a gip/glp1 co-agonist for diabetes
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
CN116726362A (zh) * 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
CN110642935A (zh) * 2019-09-25 2020-01-03 成都奥达生物科技有限公司 一种替瑞帕肽类似物
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
WO2022079639A1 (en) * 2020-10-17 2022-04-21 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7672503B2 (ja) * 2021-05-28 2025-05-07 広東衆生睿創生物科技有限公司 ポリペプチドの調製およびその使用
WO2023044290A1 (en) 2021-09-15 2023-03-23 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
HRP20251161T1 (hr) 2021-09-27 2025-11-21 Terns Pharmaceuticals, Inc. Benzimidazol karboksilne kisele kao agonisti glp-1r
TW202334129A (zh) 2021-10-25 2023-09-01 美商拓臻製藥公司 作為ｇｌｐ—１ｒ促效劑的化合物
JP2024545887A (ja) * 2022-01-10 2024-12-13 ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド 安定した受容体アゴニストの医薬組成物、製造方法及びその応用
US20250171499A1 (en) * 2022-01-18 2025-05-29 Viking Therapeutics, Inc. Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
WO2023164050A1 (en) 2022-02-23 2023-08-31 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法
KR20250029908A (ko) * 2022-06-30 2025-03-05 일라이 릴리 앤드 캄파니 티르제파티드 조성물 및 용도
TW202412835A (zh) * 2022-09-23 2024-04-01 大陸商博瑞生物醫藥(蘇州)股份有限公司 一種glp-1和gip雙受體激動劑藥物組合物及其用途
CN120379686A (zh) * 2022-10-19 2025-07-25 伊莱利利公司 含防腐剂的gip/glp激动剂组合物
CN115651075B (zh) * 2022-12-12 2023-04-11 杭州信海医药科技有限公司 一种Tirzepatide的合成方法
AR132137A1 (es) * 2023-03-15 2025-05-28 Viking Therapeutics Inc Composiciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos
TW202506131A (zh) 2023-04-07 2025-02-16 美商拓臻製藥公司 ＧＬＰ－１Ｒ及ＴＨＲβ激動劑之組合以及其使用方法
KR20240167410A (ko) * 2023-05-19 2024-11-26 주식회사 아울바이오 티르제파타이드를 포함하는 미립구, 이의 제조방법, 및 이를 포함하는 약학적 조성물
WO2024248572A1 (ko) * 2023-06-02 2024-12-05 주식회사 지투지바이오 터제파타이드 또는 이의 약학적으로 허용가능한 염을 포함하는 서방성 미립구 제제 및 이의 제조방법
WO2025087344A1 (en) * 2023-10-25 2025-05-01 Beta Pharma, Inc. Glp1-r/gipr dual peptide agonists and use thereof
WO2025141472A1 (en) * 2023-12-27 2025-07-03 Alembic Pharmaceuticals Limited Stable pharmaceutical compositions comprising tirzepatide
WO2025191149A1 (en) 2024-03-15 2025-09-18 Krka, D.D., Novo Mesto Pharmaceutical composition comprising dual gip and glp-1 receptor agonist
EP4656183A1 (en) 2024-05-31 2025-12-03 Galenicum Health SLU Tirzepatide compositions and preparation method
US12434008B1 (en) 2025-02-26 2025-10-07 Genzyme Corporation Lock ring for a medicament delivery device
US12465697B1 (en) 2025-02-26 2025-11-11 Genzyme Corporation Medicament delivery device
US12420017B1 (en) 2025-02-26 2025-09-23 Genzyme Corporation Damping device for a medicament delivery device

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06247870A (ja) * 1993-02-23 1994-09-06 Ajinomoto Co Inc インターロイキン−６を含有する医薬製剤
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
JP3723857B2 (ja) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 ヒト成長ホルモン含有水性医薬組成物
DK1069912T3 (da) * 1998-04-03 2007-11-12 Novartis Vaccines & Diagnostic Injicerbare IGF-formuleringer, der indeholder succinat som puffermiddel
BR0111562A (pt) 2000-06-16 2003-04-15 Lilly Co Eli Análogos de peptìdeo 1 semelhantes ao glucagon
US7977376B2 (en) * 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
DK1412384T3 (da) 2001-06-28 2008-04-28 Novo Nordisk As Stabil formulering af modificeret GLP-1
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
CN104826116A (zh) * 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
JP5248113B2 (ja) 2004-11-12 2013-07-31 ノヴォ ノルディスク アー／エス ペプチドの安定な処方
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
EA011166B1 (ru) 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
BRPI0613731A2 (pt) * 2005-07-12 2011-02-01 Renovo Ltd composição farmacêutica, recipiente enchido previamente, bem como uso de um açúcar para aprimorar a recuperação e/ou aumentar a atividade biológica de um membro da superfamìlia tgf-beta
KR101438839B1 (ko) * 2006-04-14 2014-10-02 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
EP2066337A2 (en) 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen
EA201070121A1 (ru) 2007-07-10 2010-06-30 Эли Лилли Энд Компани Лекарственная форма, содержащая слитый белок glp-1-fc
CN101822822A (zh) * 2009-03-04 2010-09-08 北京德众万全药物技术开发有限公司 一种普兰林肽的药物组合物及其制备方法
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
UA110026C2 (uk) 2010-03-01 2015-11-10 Пристрій для автоматичного виконання ін'єкції з механізмом затримки, який включає в себе пересувальний елемент подвійного призначення
PE20140724A1 (es) * 2011-06-22 2014-07-10 Univ Indiana Res & Tech Corp Coagonistas del receptor de glucagon/glp-1
AR090937A1 (es) 2012-05-03 2014-12-17 Zealand Pharma As Compuestos agonista duales de gip-glp-1 y metodos para usarlos
PL2866825T3 (pl) 2012-07-01 2021-02-22 Novo Nordisk A/S <div>ZASTOSOWANIE PEPTYDÓW GLP-1 O PRZEDŁUŻONYM DZIAŁANIU</div>
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
US20150290328A1 (en) 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
CN105120887A (zh) 2013-04-05 2015-12-02 诺和诺德保健股份有限公司 生长激素化合物制剂
WO2014202780A1 (en) 2013-06-21 2014-12-24 Novo Nordisk A/S Novel uses of glp-1 receptor agonists in patients treated with insulin and/or suffering from type 1 diabetes
CN105451776B (zh) 2013-08-15 2020-04-17 诺和诺德股份有限公司 Glp-1衍生物及其用途
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2016077220A1 (en) * 2014-11-10 2016-05-19 Mb2 Llc Gip/glp-1 co-agonist peptides for human administration
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
MA53353A (fr) * 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物

Also Published As

Publication number Publication date
RS64288B9 (sr) 2023-11-30
US12453755B2 (en) 2025-10-28
BR112020023452A2 (pt) 2021-02-23
JP7700205B2 (ja) 2025-06-30
DK3810201T5 (da) 2023-08-21
LT3810201T (lt) 2023-07-25
MX2020013727A (es) 2021-03-02
MX2025004309A (es) 2025-05-02
AU2019289110A1 (en) 2021-01-21
EP4257185A3 (en) 2024-01-17
ES2953740T3 (es) 2023-11-15
CN119424616B (zh) 2025-11-07
HUE063059T2 (hu) 2023-12-28
PE20210049A1 (es) 2021-01-08
US20240226229A1 (en) 2024-07-11
TWI705820B (zh) 2020-10-01
PH12020552215A1 (en) 2021-06-28
KR20210010572A (ko) 2021-01-27
HRP20230748T1 (hr) 2023-10-27
AR115542A1 (es) 2021-01-27
AU2022279524A1 (en) 2023-02-02
CA3103469A1 (en) 2019-12-26
CR20200634A (es) 2021-01-21
EP3810201A2 (en) 2021-04-28
ECSP20082717A (es) 2021-01-29
JOP20200335A1 (ar) 2020-12-20
US12453756B2 (en) 2025-10-28
MA52965A (fr) 2021-04-28
AU2024266715A1 (en) 2024-12-19
JP2021506952A (ja) 2021-02-22
EP3810201B9 (en) 2023-08-02
PE20242299A1 (es) 2024-12-11
WO2019245893A2 (en) 2019-12-26
IL295433A (en) 2022-10-01
KR20230058172A (ko) 2023-05-02
CN119424616A (zh) 2025-02-14
US11918623B2 (en) 2024-03-05
EP4257185A2 (en) 2023-10-11
KR20250090374A (ko) 2025-06-19
JP2021167314A (ja) 2021-10-21
FI3810201T3 (fi) 2023-08-17
SI3810201T1 (sl) 2023-08-31
US20250186544A1 (en) 2025-06-12
JP2025102837A (ja) 2025-07-08
CN119424615A (zh) 2025-02-14
US20190388502A1 (en) 2019-12-26
EP3810201B1 (en) 2023-06-07
NZ770042A (en) 2024-07-26
CA3103469C (en) 2024-04-09
SG11202012744UA (en) 2021-01-28
IL279504B (en) 2022-09-01
ZA202007162B (en) 2025-05-28
IL279504A (en) 2021-01-31
EA202092713A1 (ru) 2021-04-05
JP6896945B2 (ja) 2021-06-30
KR102523489B1 (ko) 2023-04-21
MD3810201T2 (ro) 2023-11-30
PT3810201T (pt) 2023-07-04
JP2024041808A (ja) 2024-03-27
JP7413315B2 (ja) 2024-01-15
US20250367253A1 (en) 2025-12-04
IL295433B1 (en) 2023-11-01
US11357820B2 (en) 2022-06-14
US20220273762A1 (en) 2022-09-01
CL2020003359A1 (es) 2021-06-25
KR20240060873A (ko) 2024-05-08
IL295433B2 (en) 2024-03-01
AU2019289110B2 (en) 2022-10-06
WO2019245893A3 (en) 2020-03-12
MA52965B1 (fr) 2023-08-31
CN112312926A (zh) 2021-02-02
PL3810201T3 (pl) 2023-09-25
TW202015717A (zh) 2020-05-01
RS64288B1 (sr) 2023-07-31

Similar Documents

Publication Publication Date Title
DK3810201T3 (da) GIP/GLP1-agonist-sammensætninger
IL279827A (en) Gip/glp1 co-agonist compounds
IL283692A (en) Novel composition
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
EP3849598A4 (en) Anti-trem-2 agonist antibodies
DK3890488T3 (da) Herbicide sammensætninger
EP3823584A4 (en) DETERGENT COMPOSITION
DK3924443T3 (da) Compositions
EP3871694A4 (en) COMPOSITION
DK3840596T3 (da) Sammensætning
EP3812426A4 (en) CURABLE COMPOSITION
EP3897866C0 (en) ANTIMICROBIAL COMPOSITION
EP4079787A4 (en) CURABLE COMPOSITION
DK3746054T3 (da) Sammensætninger omfattende berberin
EP3981256A4 (en) COMPOSITION
DK3808747T3 (da) Imidazopyridinon-forbindelse
PT3765379T (pt) Composições
EP3941942A4 (en) Composition
EP4079788A4 (en) Curable composition
EP3954721A4 (en) COMPOSITION
EP3875451A4 (en) TLR8 AGONIST
EP3829532A4 (en) KERATIN COMPOSITIONS
EP3821574C0 (en) Digital isolator
EP3741814C0 (en) COMPOSITION
EP3900790A4 (en) COMPOSITION